ArticleJournal of ginseng research2025
Synergistic effects of ginsenoside Rb1 and peroxiredoxin 6 in enhancing myocardial injury treatment through anti-inflammatory, anti-oxidative, and anti-apoptotic mechanisms.
Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ginsenosides Rh2 and Rg3 in first-line combination therapy: Prospects for rapid clinical translation in drug-resistant triple-negative breast cancer.Journal of ginseng research · 2026Review
- Ginsenosides fromJournal of ginseng research · 2026Review
- Review
- Therapeutic effects of pomegranate hot-water extract via inhibition of apoptosis and oxidative stress in a DHEA-induced mouse model of PCOS.Integrative medicine research · 2026Article
- Cellular and molecular regulation of skin by ginseng and its bioactive Constituents: A review of studies from 2021 to 2025.Journal of ginseng research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Ginsenosides have notable bioactivity in treating cardiovascular diseases, but the mechanisms of their combined use with Peroxiredoxin 6 (PRDX6) in myocardial injury remain unclear. This study explores the synergistic effects of Ginsenoside Rb1 (Gs-Rb1) and PRDX6, aiming to provide a theoretical foundation for their therapeutic potential. Methods: We established a rat model of isoproterenol (ISO)-induced myocardial injury and observed that combination therapy was more effective than single-drug treatments, as shown by ECG monitoring and Masson staining. We performed RNA sequencing (RNA-Seq) on the combination therapy group and the ISO group. The results indicated that, compared to the ISO group, the combination therapy alleviated myocardial injury by reducing inflammation, oxidative stress, and apoptosis. Further analyses, including cell morphology, apoptosis rates, HE staining, ROS fluorescence intensity, and inflammation-related proteins, confirmed that the combination therapy successfully inhibited apoptosis, managed oxidative stress, and lessened inflammation. Results: Combined treatment with Gs-Rb1 and PRDX6 significantly inhibited cardiac tissue fibrosis in rats, leading to a marked decrease in serum CK and LDH levels. RNA-seq analysis revealed upregulated genes related to lipid metabolism and small molecule biosynthesis, while downregulated genes were associated with oxidative stress, inflammation, and apoptosis. Validation experiments confirmed the combined treatment's significant inhibition of apoptosis, ROS activity, and inflammation. These results support the effectiveness of the two-drug combination in suppressing key biological processes in cardiac tissue, suggesting potential mechanisms for combating cardiac fibrosis. Conclusion: This study clarifies how Gs-Rb1 and PRDX6 work together to protect against myocardial damage, demonstrating that their combined therapy reduces inflammation, apoptosis, and oxidative stress. This highlights a new avenue for developing ginseng-based treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.